161 related articles for article (PubMed ID: 12384449)
1. Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation.
Reddy P; Teshima T; Hildebrandt G; Duffner U; Maeda Y; Cooke KR; Ferrara JL
Blood; 2002 Nov; 100(9):3429-31. PubMed ID: 12384449
[TBL] [Abstract][Full Text] [Related]
2. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
3. Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.
Tsukada N; Kobata T; Aizawa Y; Yagita H; Okumura K
Blood; 1999 Apr; 93(8):2738-47. PubMed ID: 10194454
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease.
Pan L; Teshima T; Hill GR; Bungard D; Brinson YS; Reddy VS; Cooke KR; Ferrara JL
Blood; 1999 Jun; 93(12):4071-8. PubMed ID: 10361103
[TBL] [Abstract][Full Text] [Related]
5. The contribution of cytotoxic and noncytotoxic function by donor T-cells that support engraftment after allogeneic bone marrow transplantation.
Jiang Z; Adams GB; Hanash AM; Scadden DT; Levy RB
Biol Blood Marrow Transplant; 2002; 8(11):588-96. PubMed ID: 12463477
[TBL] [Abstract][Full Text] [Related]
6. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.
Schmaltz C; Alpdogan O; Horndasch KJ; Muriglan SJ; Kappel BJ; Teshima T; Ferrara JL; Burakoff SJ; van den Brink MR
Blood; 2001 May; 97(9):2886-95. PubMed ID: 11313285
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects.
Reddy P; Teshima T; Hildebrandt G; Williams DL; Liu C; Cooke KR; Ferrara JL
Blood; 2003 Apr; 101(7):2877-85. PubMed ID: 12433681
[TBL] [Abstract][Full Text] [Related]
8. Th2 and Tc2 cells in the regulation of GVHD, GVL, and graft rejection: considerations for the allogeneic transplantation therapy of leukemia and lymphoma.
Fowler DH; Gress RE
Leuk Lymphoma; 2000 Jul; 38(3-4):221-34. PubMed ID: 10830730
[TBL] [Abstract][Full Text] [Related]
9. Donor T cells lacking Fas ligand and perforin retain the capacity to induce severe GvHD in minor histocompatibility antigen mismatched bone-marrow transplantation recipients.
Marks L; Altman NH; Podack ER; Levy RB
Transplantation; 2004 Mar; 77(6):804-12. PubMed ID: 15077018
[TBL] [Abstract][Full Text] [Related]
10. Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect.
Clouthier SG; Cooke KR; Teshima T; Lowler KP; Liu C; Connolly K; Ferrara JL
Biol Blood Marrow Transplant; 2003 Sep; 9(9):592-603. PubMed ID: 14506661
[TBL] [Abstract][Full Text] [Related]
11. Major histocompatibility complex-mismatched allogeneic bone marrow transplantation using perforin and/or Fas ligand double-defective CD4(+) donor T cells: involvement of cytotoxic function by donor lymphocytes prior to graft-versus-host disease pathogenesis.
Jiang Z; Podack E; Levy RB
Blood; 2001 Jul; 98(2):390-7. PubMed ID: 11435308
[TBL] [Abstract][Full Text] [Related]
12. T-cell subsets mediate graft-versus-myeloid leukemia responses via different cytotoxic mechanisms.
Hsieh MH; Patterson AE; Korngold R
Biol Blood Marrow Transplant; 2000; 6(3):231-40. PubMed ID: 10871148
[TBL] [Abstract][Full Text] [Related]
13. Differential Effect of MyD88 Signal in Donor T Cells on Graft-versus-Leukemia Effect and Graft-versus-Host Disease after Experimental Allogeneic Stem Cell Transplantation.
Lim JY; Ryu DB; Lee SE; Park G; Choi EY; Min CK
Mol Cells; 2015 Nov; 38(11):966-74. PubMed ID: 26552489
[TBL] [Abstract][Full Text] [Related]
14. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
15. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
[TBL] [Abstract][Full Text] [Related]
17. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
18. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions.
Blazar BR; Lees CJ; Martin PJ; Noelle RJ; Kwon B; Murphy W; Taylor PA
J Immunol; 2000 Nov; 165(9):4901-9. PubMed ID: 11046015
[TBL] [Abstract][Full Text] [Related]
19. Correlation between enhancement of graft-versus-leukemia effects following allogeneic bone marrow transplantation by rIL-2 and increased frequency of cytotoxic T-lymphocyte precursors in murine myeloid leukemia.
Leshem B; Vourka-Karussis U; Slavin S
Cytokines Cell Mol Ther; 2000 Sep; 6(3):141-7. PubMed ID: 11140883
[TBL] [Abstract][Full Text] [Related]
20. Transplantation of Graft Anti-Host Cytotoxic T Lymphocytes Along with Allogeneic Bone Marrow Skips Macrophage-Induced Graft-Versus-Host Disease.
Yoshida R; Yamana H; Hayashi M; Yasuda E; Shibayama Y; Hirose Y; Tanigawa N; Uchiyama K; Kubota T
J Interferon Cytokine Res; 2021 Sep; 41(9):310-318. PubMed ID: 34543129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
